Drug intelligence / Profile preview

inulin-type fructans

Development stage
Preclinical
Lead developer
Beneo
Modality
Microbiome Therapeutics
Administration
Oral
01

Overview

Inulin-type fructans are a **non-digestible prebiotic fiber mixture** composed mainly of inulin and shorter-chain fructooligosaccharides/oligofructose that is administered orally to modulate the gut microbiota rather than to act through a single receptor target. In the provided human studies, ITF was used as a nutritional intervention in adults with overweight or obesity, including a randomized placebo-controlled trial in obese women receiving 16 g/day for 3 months, where treatment increased **Bifidobacterium** species and *Faecalibacterium prausnitzii*, reduced circulating lipopolysaccharide-associated metabolic endotoxemia, and was associated with modest changes in adiposity and metabolic markers. ITF is better characterized as a **dietary prebiotic/nutraceutical ingredient** than a conventional pharmaceutical asset; it has also been studied in snack-bar formulations with whey protein for appetite control and, in separate nonclinical work, in obesity-associated inflammation models.

Other names
inulin-type fructansITF prebioticsITFinulin/oligofructose 50/50 mixoligofructose-enriched inulininulin and oligofructoseSynergy 1Synergy1Synergy-1

Beyond the preview

Go deeper on inulin-type fructans.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on inulin-type fructans.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call